Second, the current analysis primarily focuses on clinicopathological characteristics and does not incorporate molecular markers—such as HER2, EBV, or epigenetic alterations—that could elucidate the biological differences between GCC and GNCC. This evidence concerns the gene ERBB2 and goblet cell carcinoma.